Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer

Hereditary Breast Cancer Clinical Trial

— BRCAsearch  

Official title:

BRCAsearch: A Population Based Prospective Study on Screening for BRCA1 and BRCA2 Germline Mutations in Patients With Newly Diagnosed Breast Cancer Treated in Southern Sweden.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02557776
• Other study ID #: Dnr 2009/659
• Status: Completed
• Phase: N/A
• Start date: February 2015
• Est. completion date: March 2018

Study information

• Verified date: February 2019
• Source: Lund University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall purpose of the study is to evaluate a method for offering mutation analysis of BRCA1 and BRCA2 to all patients with newly diagnosed breast cancer, regardless of age at diagnosis and family history. Information about the study as well as pre-test genetic counseling will primarily be given in a written way. In addition to that, if a study participant wishes to, she can also receive pre-test telephone genetic counseling.

Description:

Study population:

All patients with newly diagnosed breast cancer in southern Sweden are offered inclusion in the SCAN-B study at the time of diagnosis pre-surgery. If they consent to that, a part of the tumor is sent to a lab in Lund, Sweden, for research purposes (RNA sequencing etc.). Patients that are included in the SCAN-B study are eligible for inclusion in BRCAsearch, see inclusion and exclusion criteria.

Study procedure (summary):

1. An envelope with written information is given to the patient at the visit to the surgeon the week after surgery. This envelope contains a written genetic counseling, information about the study, an informed consent form, psychosocial questionnaires and our contact information (telephone, e-mail). The patient can contact a genetic counselor for pre-test telephone genetic counseling if she wishes to.

2. BRCA1 and BRCA2 are analyzed by full sequencing.

3. Non-carriers are informed about the test result with a letter. Mutation carriers and VUS (variants of uncertain significance) are telephoned and given a time for an appointment at the Department of Clinical Genetics within a week.

4. Psychosocial self-reported questionnaires (HAD scale, EORTC QLQ-C30, EORTC QLQ-BR23) are delivered at 3 times: At invitation to the study, one month after information about test result, and one year after information about test result.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 542
• Est. completion date: March 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient is included in the SCAN-B study.

2. The patient is recently diagnosed with an invasive breast cancer or a ductal cancer in situ.

3. The patient has signed an informed consent form.

Exclusion Criteria:

1. The patient is unable to understand the written information in Swedish.

2. The patient's psychological state, due to chronic och temporary reasons, is such that one could suspect that information about the study or genetic testing could be substantially detrimental to the psychological well-beeing.

Related Conditions & MeSH terms

• Breast Neoplasms
• Hereditary Breast Cancer

Intervention

Genetic:
• Germline genetic testing of BRCA1 and BRCA2

Locations

Country	Name	City	State
Sweden	Helsingborg Hospital, Dept of Surgergy	Helsingborg
Sweden	Kristianstad Central Hospital	Kristianstad

Sponsors (1)

Lead Sponsor	Collaborator
Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of BRCA1/2 mutations in an unselected breast cancer cohort in southern Sweden		3 years
Primary	Uptake of genetic testing		3 years
Primary	Proportion of the mutation carriers that do not fulfil current criteria for genetic testing		3 years
Secondary	How many of the patients that contact us for questions		3 years
Secondary	How uptake of genetic testing varies with the age at diagnosis	Proportion of patients tested in seperate age groups of 10 years.	3 years
Secondary	The patients' attitudes towards the method used for identifying mutation carriers	A questionnaire with 7 general questions (answers graded 1 to 4, where 1 = not at all, and 4 = to a high extent) will be sent the participants one year after the test results were delivered. The questions are in Swedish; translated to English, examples of questions are: "are you content with the method used in the study for informtion?", "would yout have liked to have more oral information?", "are you content with having gone through genetic testing?", "would you recommend a friend of you with breast cancer to pursue genetic testing in the way that you have done?"	3 years
Secondary	Psychosocial comparisons between mutation carriers and non-carriers	Matched comparisons between mutation carriers and non-carriers for psychosocial endpoints will be done in a nested case-control study, where two controls are selected for each mutation carrier on the basis of age, adjuvant chemotherapy, stage and ER status.	4 years